LT2750768T - Decitabino darinio kompozicijos - Google Patents
Decitabino darinio kompozicijosInfo
- Publication number
- LT2750768T LT2750768T LTEP12759857.1T LT12759857T LT2750768T LT 2750768 T LT2750768 T LT 2750768T LT 12759857 T LT12759857 T LT 12759857T LT 2750768 T LT2750768 T LT 2750768T
- Authority
- LT
- Lithuania
- Prior art keywords
- derivative formulations
- decitabine
- decitabine derivative
- formulations
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161529081P | 2011-08-30 | 2011-08-30 | |
PCT/US2012/052816 WO2013033176A1 (en) | 2011-08-30 | 2012-08-29 | Decitabine derivative formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2750768T true LT2750768T (lt) | 2019-02-11 |
Family
ID=46875963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP12759857.1T LT2750768T (lt) | 2011-08-30 | 2012-08-29 | Decitabino darinio kompozicijos |
Country Status (26)
Country | Link |
---|---|
US (4) | US9381207B2 (lt) |
EP (2) | EP3431142B1 (lt) |
JP (2) | JP6038921B2 (lt) |
KR (1) | KR102004559B1 (lt) |
CN (2) | CN103945902B (lt) |
AU (2) | AU2012302051B2 (lt) |
BR (1) | BR112014004779B1 (lt) |
CA (1) | CA2845585C (lt) |
CO (1) | CO6950470A2 (lt) |
CY (1) | CY1122168T1 (lt) |
DK (1) | DK2750768T3 (lt) |
ES (1) | ES2702495T3 (lt) |
HK (1) | HK1199715A1 (lt) |
HU (1) | HUE042327T2 (lt) |
IL (2) | IL231209A0 (lt) |
LT (1) | LT2750768T (lt) |
MX (1) | MX359314B (lt) |
MY (2) | MY186676A (lt) |
PH (1) | PH12018501678A1 (lt) |
PL (1) | PL2750768T3 (lt) |
PT (1) | PT2750768T (lt) |
RU (1) | RU2605289C2 (lt) |
SG (1) | SG2014013395A (lt) |
UA (1) | UA116528C2 (lt) |
WO (1) | WO2013033176A1 (lt) |
ZA (1) | ZA201701083B (lt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
CN103945902B (zh) | 2011-08-30 | 2018-07-20 | 阿斯泰克斯制药公司 | 地西他滨衍生物制剂 |
SG11201506727RA (en) * | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
EP3177289A4 (en) | 2014-08-08 | 2018-03-21 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CA2991167A1 (en) * | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
MX2020001233A (es) | 2017-08-03 | 2020-07-20 | Otsuka Pharma Co Ltd | Compuesto farmaceutico y metodos de purificacion del mismo. |
WO2019157200A1 (en) | 2018-02-07 | 2019-08-15 | Lovelace Respiratory Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
CN116059404A (zh) | 2018-06-11 | 2023-05-05 | 加利福尼亚大学董事会 | 用以治疗眼睛疾病的脱甲基化 |
KR20220083704A (ko) * | 2019-10-18 | 2022-06-20 | 후지필름 와코 준야쿠 가부시키가이샤 | 포스포아미다이트 활성화제 |
US20220096507A1 (en) * | 2020-07-01 | 2022-03-31 | Sandoz Ag | Parenteral Pharmaceutical Composition Comprising Azacitidine or Decitabine in DMSO |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133858A (en) * | 1954-03-24 | 1964-05-19 | Abbott Lab | Stable thiobarbituric acid solution |
CH527207A (de) | 1968-05-08 | 1972-08-31 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen |
DE2105468A1 (en) | 1970-04-23 | 1971-11-18 | Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen | 1-glycosyl-5-aza-cytosines prepn |
US5157120A (en) | 1980-09-16 | 1992-10-20 | Syntex (U.S.A.) Inc. | Guanine derivatives |
US4855304A (en) | 1985-01-10 | 1989-08-08 | Repligen Corporation | Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals |
JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
GB8612826D0 (en) | 1986-05-27 | 1986-07-02 | Boots Co Plc | Insecticidal compositions |
DE3712786A1 (de) | 1987-04-15 | 1988-11-03 | Merck Patent Gmbh | Verfahren und mittel zur bestimmung von nucleinsaeuren |
CS269077B1 (cs) | 1987-10-01 | 1990-04-11 | Piskala Alois | Způsob přípravy 5-azacytosinů |
US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
US4904770A (en) | 1988-03-24 | 1990-02-27 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
US5324831A (en) | 1988-04-06 | 1994-06-28 | The United States Of America As Represented By The Secretary Of Health And Human Services | Phosphoramidite reagent for chemical synthesis of modified DNA |
PT93772A (pt) | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
ATE205850T1 (de) | 1991-07-05 | 2001-10-15 | Pro Neuron Inc | Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden |
IL103311A0 (en) | 1991-10-07 | 1993-03-15 | Univ Johns Hopkins | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers |
JPH05219974A (ja) | 1992-02-13 | 1993-08-31 | Mitsui Petrochem Ind Ltd | トロパンアルカロイドの製造方法 |
JPH05246891A (ja) * | 1992-03-09 | 1993-09-24 | Kobayashi Seiyaku Kogyo Kk | 安定な抗膵炎用注射液 |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
AU6081294A (en) | 1993-05-14 | 1994-12-12 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
AU1061395A (en) | 1993-11-30 | 1995-06-19 | Mcgill University | Inhibition of dna methyltransferase |
US6432924B1 (en) | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
US20030104576A1 (en) | 1994-10-07 | 2003-06-05 | Jonathan W. Nyce | Dna construct, composition, formulations & methods for making the construct & for modulating expression |
CA2221411A1 (en) | 1995-05-19 | 1996-11-21 | Phytera, Inc. | Manipulation of plant cell and tissue cultures |
AU706026B2 (en) | 1995-06-06 | 1999-06-10 | Case Western Reserve University | Myogenic differentiation of human mesenchymal stem cells |
JPH11513992A (ja) | 1995-12-22 | 1999-11-30 | イースト・カロライナ・ユニバーシティ | シチジンデアミナーゼまたはデオキシシチジンデアミナーゼの過剰発現を伴う疾患を治療するための薬剤および方法 |
WO1998016186A2 (en) | 1996-10-16 | 1998-04-23 | Icn Pharmaceuticals, Inc. | Monocyclic l-nucleosides, analogs and uses thereof |
US6423692B2 (en) | 1997-04-24 | 2002-07-23 | Dana-Farber Cancer Institute, Inc. | Method of enhancing the effectiveness of DCK phosphorylated molecules |
US6153383A (en) | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
JP4768121B2 (ja) | 1998-02-05 | 2011-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Mageファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用 |
EP1123111B1 (en) | 1998-10-19 | 2004-09-15 | Methylgene, Inc. | Modulation of dna methyltransferase expression by combination therapy |
JP3793693B2 (ja) | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
AU3469400A (en) | 1999-01-05 | 2000-07-24 | Clarence C. Lee | Pharmaceutical compositions for treatment of diseased tissues |
AU4347500A (en) | 1999-04-13 | 2000-11-14 | Rutgers, The State University Of New Jersey | Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity |
EP1206234A4 (en) | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
JP2001163776A (ja) * | 1999-09-30 | 2001-06-19 | Nisshin Oil Mills Ltd:The | 安定化された液剤 |
EP1224303A2 (en) | 1999-10-18 | 2002-07-24 | Emory University | Tms1 compositions and methods of use |
WO2001069262A1 (en) | 2000-03-15 | 2001-09-20 | University Of Massachusetts | ERβ-MEDIATED GENE EXPRESSION |
CN1460181A (zh) | 2000-09-08 | 2003-12-03 | 汉城国立大学工业基金会 | 参与细胞衰老的核酸序列和蛋白质 |
JP2004536026A (ja) * | 2000-11-28 | 2004-12-02 | トランスフォーム ファーマシューティカルズ,インコーポレーティッド. | パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤 |
WO2002053138A2 (en) | 2001-01-02 | 2002-07-11 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
EP1355916B1 (en) | 2001-01-22 | 2007-01-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP2002223753A (ja) | 2001-01-30 | 2002-08-13 | Hitachi Ltd | 薬物応答解析用オリゴヌクレオチドアレイ |
EP1357930B1 (en) | 2001-02-05 | 2005-11-02 | Innoventus Project AB | Histidine-rich glycoprotein (hrgp) for inhibiting angiogenesis |
US6613753B2 (en) | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
AU2002252183A1 (en) | 2001-03-06 | 2002-09-19 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
US20060194275A1 (en) | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
KR20040005936A (ko) | 2001-04-26 | 2004-01-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 공동약물을 함유하는 서방 약물 전달 시스템 |
US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
JP2004536596A (ja) | 2001-06-08 | 2004-12-09 | ユー.エス. ジェノミクス, インコーポレイテッド | メチル化状態に基づいて核酸を分析するための方法および生成物 |
JP2002370939A (ja) | 2001-06-12 | 2002-12-24 | Taisho Pharmaceut Co Ltd | 育毛剤 |
SE0102627L (sv) | 2001-07-27 | 2002-11-19 | Geneinvent Bbl Ab | Vektorer motståndskraftiga mot metylering |
US20030045497A1 (en) | 2001-07-27 | 2003-03-06 | Geneinvent Bbl Ab | Methylation resistant vectors |
WO2003012085A1 (en) | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
WO2003020252A2 (en) | 2001-09-05 | 2003-03-13 | Stragen Pharma Sa | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
IN2014DN10834A (lt) | 2001-09-17 | 2015-09-04 | Psivida Inc | |
US20030158598A1 (en) | 2001-09-17 | 2003-08-21 | Control Delivery Systems, Inc. | System for sustained-release delivery of anti-inflammatory agents from a coated medical device |
CA2461227C (en) | 2001-09-24 | 2012-05-15 | Jessie L.-S Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
US7432050B2 (en) | 2001-10-05 | 2008-10-07 | Case Western Reserve University | Methods and compositions for detecting colon cancers |
KR100616369B1 (ko) | 2001-11-08 | 2006-08-28 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | 벼의 트랜스포존 유전자 |
YU44404A (sh) | 2001-11-23 | 2006-08-17 | Chugai Seiyaku Kabushiki Kaisha | Postupak za identifikovanje ciljnih enzima tumora |
US7771998B2 (en) | 2001-11-29 | 2010-08-10 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
US20050080027A1 (en) | 2001-11-30 | 2005-04-14 | Markus Horer | Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors |
GB0201498D0 (en) | 2002-01-23 | 2002-03-13 | Biotech Res Ventures Pte Ltd | Materials and methods for treating cancer |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US20030147813A1 (en) | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
JP2005519610A (ja) | 2002-03-13 | 2005-07-07 | エフ.ホフマン−ラ ロシュ アーゲー | 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法 |
JP2003310293A (ja) | 2002-04-26 | 2003-11-05 | Mitsui Chemicals Inc | ヌクレオシド化合物の製造法 |
SI1507556T1 (sl) | 2002-05-02 | 2016-10-28 | Wyeth Holdings Llc | Konjugati kaliheamicinski derivat-nosilec |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
AU2003251483A1 (en) | 2002-06-05 | 2003-12-22 | Case Western Reserve University | Methods and compositions for detecting cancers |
EP1556010A4 (en) | 2002-10-31 | 2007-12-05 | Supergen Inc | PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT |
US20050037992A1 (en) | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
US7846436B2 (en) | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
ATE422367T1 (de) | 2004-05-26 | 2009-02-15 | Biovaxim Ltd | Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür |
US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
AU2005300315A1 (en) | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20060159694A1 (en) | 2004-12-29 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20070117776A1 (en) | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
US20070105792A1 (en) | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
CN101637444B (zh) * | 2006-03-17 | 2012-08-15 | 山东蓝金生物工程有限公司 | 含吉西他滨的抗癌药物缓释注射剂 |
JP2009536186A (ja) * | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
WO2009051827A1 (en) * | 2007-10-18 | 2009-04-23 | The United States Of America As Represented By The Department Of Veterans Affairs | Modulation of sodium channels by nicotinamide adenine dinucleotide |
CN101570553B (zh) * | 2008-05-04 | 2012-03-28 | 上海医药工业研究院 | 一种2-脱氧-d-核糖的衍生物及其制备方法和用途 |
CN101361718B (zh) * | 2008-09-26 | 2013-08-28 | 深圳万乐药业有限公司 | 稳定的地西他滨冻干制剂的制备方法 |
CN101787046B (zh) * | 2010-02-11 | 2012-12-26 | 福建南方制药股份有限公司 | 地西他滨的中间体化合物的制备方法 |
GB201006096D0 (en) | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
EP2614086A1 (en) | 2010-09-08 | 2013-07-17 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
CN101966157B (zh) * | 2010-10-14 | 2013-08-14 | 苏州特瑞药业有限公司 | 一种地西他滨缓释微球及其制备方法 |
BR112013026199A2 (pt) | 2011-04-15 | 2017-11-07 | Compugen Ltd | polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo |
CN103945902B (zh) | 2011-08-30 | 2018-07-20 | 阿斯泰克斯制药公司 | 地西他滨衍生物制剂 |
US9872873B2 (en) | 2012-02-06 | 2018-01-23 | Fresenius Kabi Oncology Limited | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
SG11201506727RA (en) | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
CA2991167A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
MX2020001233A (es) | 2017-08-03 | 2020-07-20 | Otsuka Pharma Co Ltd | Compuesto farmaceutico y metodos de purificacion del mismo. |
-
2012
- 2012-08-29 CN CN201280053249.8A patent/CN103945902B/zh not_active Expired - Fee Related
- 2012-08-29 MX MX2014002433A patent/MX359314B/es active IP Right Grant
- 2012-08-29 HU HUE12759857A patent/HUE042327T2/hu unknown
- 2012-08-29 DK DK12759857.1T patent/DK2750768T3/en active
- 2012-08-29 AU AU2012302051A patent/AU2012302051B2/en not_active Ceased
- 2012-08-29 WO PCT/US2012/052816 patent/WO2013033176A1/en active Application Filing
- 2012-08-29 PL PL12759857T patent/PL2750768T3/pl unknown
- 2012-08-29 CA CA2845585A patent/CA2845585C/en not_active Expired - Fee Related
- 2012-08-29 KR KR1020147008110A patent/KR102004559B1/ko active IP Right Grant
- 2012-08-29 UA UAA201403130A patent/UA116528C2/uk unknown
- 2012-08-29 LT LTEP12759857.1T patent/LT2750768T/lt unknown
- 2012-08-29 SG SG2014013395A patent/SG2014013395A/en unknown
- 2012-08-29 ES ES12759857T patent/ES2702495T3/es active Active
- 2012-08-29 PT PT12759857T patent/PT2750768T/pt unknown
- 2012-08-29 MY MYPI2017001344A patent/MY186676A/en unknown
- 2012-08-29 EP EP18177788.9A patent/EP3431142B1/en active Active
- 2012-08-29 RU RU2014112108/15A patent/RU2605289C2/ru active
- 2012-08-29 BR BR112014004779-0A patent/BR112014004779B1/pt not_active IP Right Cessation
- 2012-08-29 CN CN201810671333.5A patent/CN108635367B/zh not_active Expired - Fee Related
- 2012-08-29 EP EP12759857.1A patent/EP2750768B1/en active Active
- 2012-08-29 MY MYPI2014000485A patent/MY163296A/en unknown
- 2012-08-29 JP JP2014528539A patent/JP6038921B2/ja not_active Expired - Fee Related
- 2012-08-29 US US14/241,635 patent/US9381207B2/en active Active
-
2014
- 2014-02-18 CO CO14033684A patent/CO6950470A2/es unknown
- 2014-02-27 IL IL231209A patent/IL231209A0/en active IP Right Grant
-
2015
- 2015-01-06 HK HK15100099.3A patent/HK1199715A1/xx not_active IP Right Cessation
-
2016
- 2016-06-06 US US15/174,386 patent/US9913856B2/en active Active
- 2016-11-02 JP JP2016214862A patent/JP6257734B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-13 ZA ZA2017/01083A patent/ZA201701083B/en unknown
- 2017-07-03 AU AU2017204536A patent/AU2017204536B2/en not_active Ceased
-
2018
- 2018-01-25 US US15/879,802 patent/US10517886B2/en not_active Expired - Fee Related
- 2018-08-07 PH PH12018501678A patent/PH12018501678A1/en unknown
- 2018-09-03 IL IL261562A patent/IL261562A/en unknown
- 2018-12-19 CY CY20181101369T patent/CY1122168T1/el unknown
-
2019
- 2019-11-06 US US16/675,785 patent/US11058705B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180646T1 (hr) | Dispiropirolidinski derivat | |
ZA201701083B (en) | Decitabine derivative formulations | |
HUS1800036I1 (hu) | Tesztoszteron-készítmények | |
ZA201306016B (en) | Bendamustine formulations | |
EP2753311A4 (en) | ANTIOXIDATIVE FORMULATIONS | |
EP2687531A4 (en) | TETRAHYDROCARBOLINE DERIVATIVE | |
EP2740730A4 (en) | DIBENZOOXEPINE DERIVATIVE | |
ZA201305986B (en) | Improved insecticide formulations | |
GB201105162D0 (en) | Improved deodorant formulations | |
GB201110278D0 (en) | Formulations | |
GB201111578D0 (en) | Pharmeutical formulations | |
GB201111013D0 (en) | Formulations | |
GB201107626D0 (en) | Formulations | |
GB201107627D0 (en) | Formulations | |
GB201105410D0 (en) | Formulations | |
GB201105360D0 (en) | Formulations | |
GB201104048D0 (en) | Formulations | |
GB201104049D0 (en) | Formulations | |
GB201102795D0 (en) | Formulations |